 Sharmilan Thanendrarajan
Concepts (214)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 49 | 2024 | 3035 | 3.630 |
Why?
| | Leukemia, Plasma Cell | 2 | 2020 | 34 | 0.930 |
Why?
| | Antibodies, Bispecific | 4 | 2024 | 43 | 0.870 |
Why?
| | Neoplasms, Plasma Cell | 3 | 2024 | 39 | 0.690 |
Why?
| | Hematopoietic Stem Cell Transplantation | 5 | 2024 | 573 | 0.680 |
Why?
| | Chromosome Deletion | 2 | 2023 | 150 | 0.620 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2017 | 43 | 0.600 |
Why?
| | Bone Marrow | 9 | 2022 | 411 | 0.600 |
Why?
| | Immunotherapy, Adoptive | 4 | 2024 | 134 | 0.590 |
Why?
| | Clinical Trials as Topic | 4 | 2022 | 490 | 0.550 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2017 | 250 | 0.530 |
Why?
| | Proteasome Inhibitors | 1 | 2016 | 110 | 0.520 |
Why?
| | Humans | 57 | 2024 | 54284 | 0.520 |
Why?
| | Immunologic Factors | 1 | 2016 | 130 | 0.510 |
Why?
| | Plasma Cells | 5 | 2023 | 238 | 0.490 |
Why?
| | Immunotherapy | 1 | 2016 | 263 | 0.470 |
Why?
| | Translocation, Genetic | 5 | 2021 | 287 | 0.460 |
Why?
| | Monoclonal Gammopathy of Undetermined Significance | 3 | 2023 | 108 | 0.450 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2021 | 866 | 0.430 |
Why?
| | Antibodies, Monoclonal | 2 | 2022 | 562 | 0.430 |
Why?
| | Neutropenia | 2 | 2023 | 120 | 0.420 |
Why?
| | Stem Cell Transplantation | 4 | 2022 | 196 | 0.410 |
Why?
| | Cytokine-Induced Killer Cells | 1 | 2011 | 2 | 0.410 |
Why?
| | Mutation | 6 | 2022 | 1501 | 0.400 |
Why?
| | Neoplasms | 2 | 2012 | 1316 | 0.390 |
Why?
| | Lymphocytes | 1 | 2012 | 168 | 0.390 |
Why?
| | Evolution, Molecular | 2 | 2021 | 103 | 0.380 |
Why?
| | Prognosis | 12 | 2024 | 2118 | 0.370 |
Why?
| | Neoplasm, Residual | 5 | 2022 | 166 | 0.370 |
Why?
| | Cancer Vaccines | 1 | 2011 | 103 | 0.370 |
Why?
| | Gene Expression Profiling | 8 | 2023 | 1138 | 0.370 |
Why?
| | Survival Analysis | 7 | 2021 | 735 | 0.350 |
Why?
| | Neoplasm Recurrence, Local | 6 | 2024 | 644 | 0.350 |
Why?
| | Aged | 16 | 2021 | 10054 | 0.340 |
Why?
| | Cytokines | 1 | 2012 | 676 | 0.330 |
Why?
| | Hematologic Neoplasms | 2 | 2022 | 99 | 0.310 |
Why?
| | Neoplasm Proteins | 3 | 2020 | 359 | 0.300 |
Why?
| | Combined Modality Therapy | 4 | 2024 | 692 | 0.290 |
Why?
| | B-Cell Maturation Antigen | 5 | 2024 | 72 | 0.290 |
Why?
| | Atrial Fibrillation | 2 | 2022 | 197 | 0.280 |
Why?
| | Transplantation, Autologous | 6 | 2024 | 476 | 0.260 |
Why?
| | Fluorodeoxyglucose F18 | 4 | 2021 | 205 | 0.250 |
Why?
| | Polycomb Repressive Complex 2 | 2 | 2021 | 50 | 0.250 |
Why?
| | Pentaerythritol Tetranitrate | 1 | 2024 | 6 | 0.250 |
Why?
| | Chromosomes, Human, Pair 1 | 2 | 2023 | 113 | 0.220 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 1056 | 0.220 |
Why?
| | Positron-Emission Tomography | 3 | 2022 | 322 | 0.220 |
Why?
| | Female | 19 | 2021 | 28441 | 0.210 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2020 | 90 | 0.210 |
Why?
| | Immunoconjugates | 1 | 2022 | 38 | 0.210 |
Why?
| | Paraproteinemias | 1 | 2022 | 80 | 0.210 |
Why?
| | Aged, 80 and over | 6 | 2021 | 3431 | 0.210 |
Why?
| | Drug Approval | 1 | 2022 | 47 | 0.210 |
Why?
| | Osteolysis | 1 | 2022 | 88 | 0.210 |
Why?
| | Waldenstrom Macroglobulinemia | 1 | 2022 | 41 | 0.210 |
Why?
| | Lymphoma, B-Cell | 1 | 2022 | 62 | 0.200 |
Why?
| | Epigenomics | 1 | 2021 | 67 | 0.200 |
Why?
| | Patient Participation | 1 | 2022 | 70 | 0.200 |
Why?
| | Treatment Outcome | 7 | 2022 | 5604 | 0.200 |
Why?
| | Middle Aged | 14 | 2021 | 13088 | 0.190 |
Why?
| | Diffusion Magnetic Resonance Imaging | 2 | 2019 | 126 | 0.190 |
Why?
| | T-Lymphocytes | 4 | 2024 | 373 | 0.190 |
Why?
| | Genes, Tumor Suppressor | 2 | 2021 | 85 | 0.190 |
Why?
| | Exosome Multienzyme Ribonuclease Complex | 1 | 2020 | 14 | 0.180 |
Why?
| | Cell Cycle | 1 | 2021 | 275 | 0.180 |
Why?
| | Practice Guidelines as Topic | 1 | 2023 | 492 | 0.180 |
Why?
| | Disease Progression | 5 | 2021 | 913 | 0.180 |
Why?
| | Bone Resorption | 1 | 2022 | 326 | 0.180 |
Why?
| | Chromosomal Instability | 1 | 2019 | 17 | 0.180 |
Why?
| | Bone Diseases | 1 | 2021 | 109 | 0.180 |
Why?
| | Hematopoiesis, Extramedullary | 1 | 2019 | 10 | 0.180 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 124 | 0.180 |
Why?
| | Risk Factors | 8 | 2021 | 3935 | 0.170 |
Why?
| | Antigens, CD | 1 | 2020 | 242 | 0.170 |
Why?
| | Insulin-Like Growth Factor Binding Protein 2 | 1 | 2018 | 11 | 0.170 |
Why?
| | Healthcare Disparities | 1 | 2022 | 271 | 0.170 |
Why?
| | Male | 17 | 2021 | 27334 | 0.160 |
Why?
| | Spleen | 1 | 2019 | 186 | 0.160 |
Why?
| | Spinal Fractures | 1 | 2018 | 41 | 0.160 |
Why?
| | Phosphotransferases | 1 | 2018 | 24 | 0.160 |
Why?
| | Bacteremia | 1 | 2019 | 101 | 0.160 |
Why?
| | Adipocytes | 1 | 2018 | 129 | 0.160 |
Why?
| | Gene Rearrangement | 1 | 2018 | 76 | 0.150 |
Why?
| | Adult | 11 | 2022 | 14207 | 0.150 |
Why?
| | Hexokinase | 1 | 2017 | 18 | 0.150 |
Why?
| | Antineoplastic Agents | 2 | 2024 | 1300 | 0.150 |
Why?
| | Calcification, Physiologic | 1 | 2017 | 42 | 0.150 |
Why?
| | Epigenesis, Genetic | 1 | 2020 | 399 | 0.150 |
Why?
| | Pelvis | 1 | 2017 | 76 | 0.150 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 2 | 2022 | 106 | 0.140 |
Why?
| | Immunoglobulin Light Chains | 1 | 2017 | 101 | 0.140 |
Why?
| | Cell Proliferation | 4 | 2023 | 1096 | 0.140 |
Why?
| | Clonal Evolution | 1 | 2016 | 60 | 0.140 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2017 | 206 | 0.130 |
Why?
| | Gene Expression | 1 | 2018 | 664 | 0.130 |
Why?
| | Animals | 4 | 2024 | 14385 | 0.120 |
Why?
| | Cystatin M | 2 | 2024 | 21 | 0.120 |
Why?
| | Cross-Sectional Studies | 3 | 2023 | 1693 | 0.110 |
Why?
| | Disease-Free Survival | 3 | 2019 | 485 | 0.110 |
Why?
| | Survival Rate | 3 | 2020 | 951 | 0.110 |
Why?
| | Cardiovascular Diseases | 1 | 2017 | 476 | 0.100 |
Why?
| | Tumor Microenvironment | 2 | 2023 | 209 | 0.100 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2011 | 63 | 0.100 |
Why?
| | Recurrence | 3 | 2021 | 690 | 0.100 |
Why?
| | Mutation Rate | 2 | 2021 | 40 | 0.100 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2023 | 278 | 0.090 |
Why?
| | Disease Models, Animal | 1 | 2016 | 1639 | 0.090 |
Why?
| | Alleles | 2 | 2021 | 277 | 0.090 |
Why?
| | Genomics | 2 | 2023 | 310 | 0.090 |
Why?
| | Tumor Burden | 2 | 2020 | 142 | 0.090 |
Why?
| | Retrospective Studies | 4 | 2024 | 6432 | 0.090 |
Why?
| | Vaccination | 1 | 2011 | 294 | 0.090 |
Why?
| | Histones | 2 | 2021 | 335 | 0.080 |
Why?
| | DNA Copy Number Variations | 2 | 2021 | 114 | 0.080 |
Why?
| | Transcription Factors | 2 | 2023 | 622 | 0.080 |
Why?
| | Brain Neoplasms | 1 | 2011 | 284 | 0.080 |
Why?
| | Radiopharmaceuticals | 2 | 2021 | 238 | 0.080 |
Why?
| | Cell Differentiation | 2 | 2022 | 720 | 0.080 |
Why?
| | Models, Biological | 1 | 2011 | 823 | 0.080 |
Why?
| | Transcriptome | 2 | 2020 | 346 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 2 | 2019 | 514 | 0.070 |
Why?
| | Follow-Up Studies | 2 | 2024 | 2387 | 0.070 |
Why?
| | Imaging, Three-Dimensional | 2 | 2017 | 171 | 0.070 |
Why?
| | Biopsy | 2 | 2018 | 692 | 0.060 |
Why?
| | Arkansas | 2 | 2021 | 2100 | 0.060 |
Why?
| | Ferritins | 1 | 2024 | 31 | 0.060 |
Why?
| | Myeloid Progenitor Cells | 1 | 2023 | 19 | 0.060 |
Why?
| | X-Ray Microtomography | 1 | 2024 | 82 | 0.060 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2024 | 55 | 0.060 |
Why?
| | Antibodies | 1 | 2024 | 178 | 0.060 |
Why?
| | TNF Receptor-Associated Factor 3 | 1 | 2022 | 14 | 0.060 |
Why?
| | Mice | 2 | 2024 | 6413 | 0.050 |
Why?
| | Signal Transduction | 2 | 2021 | 1753 | 0.050 |
Why?
| | Patients | 1 | 2022 | 53 | 0.050 |
Why?
| | Geography | 1 | 2022 | 81 | 0.050 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2022 | 40 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2022 | 97 | 0.050 |
Why?
| | Oncogenes | 1 | 2021 | 63 | 0.050 |
Why?
| | Patient Selection | 1 | 2023 | 286 | 0.050 |
Why?
| | Dexamethasone | 1 | 2024 | 435 | 0.050 |
Why?
| | Syndecan-1 | 1 | 2021 | 82 | 0.050 |
Why?
| | Bone Marrow Transplantation | 1 | 2022 | 149 | 0.050 |
Why?
| | Phylogeny | 1 | 2022 | 269 | 0.050 |
Why?
| | Chromosome Aberrations | 1 | 2023 | 316 | 0.050 |
Why?
| | RANK Ligand | 1 | 2022 | 183 | 0.050 |
Why?
| | SOXC Transcription Factors | 1 | 2021 | 14 | 0.050 |
Why?
| | Transcriptional Activation | 1 | 2021 | 134 | 0.050 |
Why?
| | Remission Induction | 1 | 2021 | 221 | 0.050 |
Why?
| | Clone Cells | 1 | 2021 | 89 | 0.050 |
Why?
| | Chromatin | 1 | 2021 | 156 | 0.050 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 69 | 0.050 |
Why?
| | Cyclin D2 | 1 | 2020 | 20 | 0.050 |
Why?
| | Aneuploidy | 1 | 2020 | 23 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-maf | 1 | 2020 | 20 | 0.050 |
Why?
| | Chromosomes, Human, Pair 4 | 1 | 2020 | 30 | 0.050 |
Why?
| | Pyrimidines | 1 | 2022 | 196 | 0.050 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 105 | 0.050 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2020 | 36 | 0.050 |
Why?
| | Histone Code | 1 | 2020 | 32 | 0.050 |
Why?
| | Cyclin D1 | 1 | 2020 | 60 | 0.050 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2022 | 240 | 0.050 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2020 | 54 | 0.050 |
Why?
| | ras Proteins | 1 | 2020 | 70 | 0.050 |
Why?
| | Chromosomes, Human, Pair 14 | 1 | 2020 | 76 | 0.050 |
Why?
| | Protein Kinase Inhibitors | 1 | 2022 | 216 | 0.050 |
Why?
| | Genome, Human | 1 | 2021 | 131 | 0.050 |
Why?
| | DNA, Neoplasm | 1 | 2020 | 171 | 0.050 |
Why?
| | Health Status Disparities | 1 | 2022 | 219 | 0.040 |
Why?
| | DNA Mutational Analysis | 1 | 2020 | 217 | 0.040 |
Why?
| | Osteoclasts | 1 | 2022 | 469 | 0.040 |
Why?
| | Genetic Variation | 1 | 2020 | 253 | 0.040 |
Why?
| | Multivariate Analysis | 1 | 2021 | 643 | 0.040 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2020 | 206 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2023 | 1550 | 0.040 |
Why?
| | Pseudomonas Infections | 1 | 2019 | 54 | 0.040 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2019 | 36 | 0.040 |
Why?
| | Computational Biology | 1 | 2020 | 231 | 0.040 |
Why?
| | Fractures, Compression | 1 | 2018 | 19 | 0.040 |
Why?
| | Syndrome | 1 | 2019 | 252 | 0.040 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2018 | 52 | 0.040 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2018 | 60 | 0.040 |
Why?
| | DNA-Binding Proteins | 1 | 2021 | 462 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2020 | 520 | 0.040 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2018 | 101 | 0.040 |
Why?
| | Kidney Function Tests | 1 | 2017 | 59 | 0.040 |
Why?
| | False Positive Reactions | 1 | 2017 | 68 | 0.040 |
Why?
| | Glomerular Filtration Rate | 1 | 2017 | 138 | 0.040 |
Why?
| | Bone and Bones | 1 | 2021 | 516 | 0.040 |
Why?
| | Alkaline Phosphatase | 1 | 2017 | 99 | 0.040 |
Why?
| | Genes, ras | 1 | 2016 | 48 | 0.040 |
Why?
| | Genes, p53 | 1 | 2016 | 60 | 0.040 |
Why?
| | Amino Acid Sequence | 1 | 2018 | 767 | 0.040 |
Why?
| | Glycolysis | 1 | 2016 | 73 | 0.040 |
Why?
| | NF-kappa B | 1 | 2018 | 335 | 0.030 |
Why?
| | DNA Methylation | 1 | 2020 | 574 | 0.030 |
Why?
| | Genomic Instability | 1 | 2016 | 95 | 0.030 |
Why?
| | Models, Genetic | 1 | 2016 | 209 | 0.030 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2016 | 119 | 0.030 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2016 | 153 | 0.030 |
Why?
| | Staphylococcal Infections | 1 | 2019 | 300 | 0.030 |
Why?
| | Logistic Models | 1 | 2018 | 995 | 0.030 |
Why?
| | Heart | 1 | 2017 | 360 | 0.030 |
Why?
| | Echocardiography | 1 | 2017 | 392 | 0.030 |
Why?
| | Algorithms | 1 | 2018 | 697 | 0.030 |
Why?
| | Myocardium | 1 | 2017 | 441 | 0.030 |
Why?
| | Disease Management | 1 | 2015 | 184 | 0.030 |
Why?
| | Kidney Diseases | 1 | 2017 | 293 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2016 | 746 | 0.030 |
Why?
| | Time Factors | 1 | 2021 | 3213 | 0.030 |
Why?
| | Risk Assessment | 1 | 2018 | 1361 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2017 | 1213 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2011 | 225 | 0.020 |
Why?
| | United States | 1 | 2022 | 5217 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2017 | 1604 | 0.020 |
Why?
|
|
Thanendrarajan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|